Edition:
United States

GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

41.10USD
19 Oct 2017
Change (% chg)

$0.09 (+0.22%)
Prev Close
$41.01
Open
$40.99
Day's High
$41.24
Day's Low
$40.98
Volume
2,907,054
Avg. Vol
2,945,060
52-wk High
$44.53
52-wk Low
$37.20

Latest Key Developments (Source: Significant Developments)

GlaxoSmithKline announces mepolizumab phase III results in patients with COPD
Tuesday, 12 Sep 2017 03:57am EDT 

Sept 12 (Reuters) - GlaxoSmithKline Plc :ANNOUNCES PHASE III RESULTS PUBLISHED IN NEJM OF MEPOLIZUMAB IN PATIENTS WITH EOSINOPHILIC COPD AT RISK OF EXACERBATIONS.REGULATORY FILINGS PLANNED FOR 2017.REDUCTION IN FREQUENCY OF EXACERBATIONS OBSERVED IN METREX STUDY WAS STATISTICALLY SIGNIFICANT.‍FOR SECONDARY ENDPOINTS, STATISTICALLY SIGNIFICANT INCREASE IN TIME TO FIRST MODERATE AND SEVERE EXACERBATION IN METREX.NO NEW SAFETY CONCERNS TO KNOWN SAFETY PROFILE OF MEPOLIZUMAB WERE IDENTIFIED ON REVIEW OF DATA FROM THE STUDIES.  Full Article

Glaxosmithkline announce positive results from SLS lung study
Monday, 11 Sep 2017 03:14am EDT 

Sept 11 (Reuters) - GLAXOSMITHKLINE PLC ::GSK ANNOUNCE POSITIVE RESULTS FROM SLS LUNG STUDY.POSITIVE RESULTS FROM SALFORD LUNG STUDY (SLS) IN ASTHMA.STUDY WAS DESIGNED TO EXPLORE EFFECTIVENESS OF AN ASTHMA MEDICINE WHEN USED WITH MINIMAL INTERVENTION IN BROAD GROUP OF PEOPLE WITH ASTHMA.  Full Article

GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO
Thursday, 7 Sep 2017 07:30am EDT 

Sept 7 (Reuters) - Adaptimmune Therapeutics Plc :Adaptimmune Therapeutics Plc - ‍GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO​.Adaptimmune Therapeutics Plc - ‍Adaptimmune will receive up to £48 million ($61 million) from GSK over course of transition period​.Adaptimmune Therapeutics Plc - ‍anticipate transition of NY-ESO to GSK to be completed over coming months​.  Full Article

Paulson & Co takes share stake in Apple, dissolves share stake in Sarepta, Biogen
Monday, 14 Aug 2017 05:10pm EDT 

Aug 14 (Reuters) - Paulson & Co::Takes share stake of 12,300 shares in Apple - SEC filing.Dissolves share stake in Biogen - SEC filing.Ups share stake in T-Mobile US Inc by 46.1 percent to 6.1 million shares - SEC filing.Dissolves share stake in Sarepta Therapeutics Inc - SEC filing.Cuts share stake in GlaxoSmithKline Plc by 30.3 percent to 289,500 sponsored ADRs - SEC filing.Change in holdings are as of June 30, 2017 and compared with the previous quarter ended as of March 31, 2017​.  Full Article

Ionis to independently advance inotersen and IONIS-FB-L Rx
Friday, 11 Aug 2017 07:00am EDT 

Aug 11 (Reuters) - Ionis Pharmaceuticals Inc :Ionis to independently advance inotersen and IONIS-FB-L Rx.Ionis Pharmaceuticals Inc - Has retained all rights to inotersen and IONIS-FB-L(Rx)..Ionis Pharmaceuticals - As part of reprioritization of pipeline and strategic review of rare diseases business, GSK declined its options on both drugs.Ionis Pharmaceuticals Inc - Plans to file for marketing authorization for inotersen this year to support a commercial launch of inotersen in 2018..Ionis Pharma- Plans to initiate first phase 2 study with IONIS-FB-L(Rx) in patients with dry amd later this year, studies in other indications in 2018.  Full Article

GSK non-core tail brands could sell for 0.5-1.0 bln pounds
Wednesday, 26 Jul 2017 10:45am EDT 

July 26 (Reuters) - GlaxoSmithKline CFO Simon Dingemans tells analysts::c.130 non-core tail brands with annual sales of 0.5 billion stg could sell for 1-2x sales.  Full Article

GSK CEO comments on Q2 results, business priorities
Wednesday, 26 Jul 2017 07:31am EDT 

July 26 (Reuters) - GlaxoSmithKline CEO Emma Walmsley told reporters::Ceo says absolutely committed to three-business structure of group.Ceo says business model provides stability of cash flows.Ceo says says will make progressive withdrawal from tanzeum diabetes business in u.s..Ceo says one m&a area where will be quite focused is early-stage pharma deals to bolster pipeline.Ceo says should not expect research and development budget to come down as result of pipeline review.Ceo says research and development spend per drug asset has been too low in the past.Ceo says does not want to put a number on future potential job losses.Ceo says encouraged by more pragmatic approach from uk government on brexit following recent letter from ministers.Ceo says.Ceo says wants long brexit transition and as much mutual drug recognition as possible.Ceo says absolute minimum brexit transition period needs to be 2 years, would like it to be longer.Ceo says partnership could be an option for oncology research and development assets.Ceo says would be 'delighted' to take on rest of consumer business but sale of stake up to novartis.Ceo says consolidation of u.s. Payers means pressure on drug prices will continue.  Full Article

ViiV announces positive results from DAWNING
Tuesday, 25 Jul 2017 08:30am EDT 

July 25 (Reuters) - Glaxosmithkline Plc ::VIIV ANNOUNCES POSITIVE RESULTS FROM DAWNING.VIIV HEALTHCARE, MAJORITY OWNED BY GSK, WITH PFIZER AND SHIONOGI AS SHAREHOLDERS, ANNOUNCED POSITIVE INTERIM RESULTS FROM DAWNING.  Full Article

GlaxoSmithKline says ViiV announces results from NEAT 022 study
Tuesday, 25 Jul 2017 08:30am EDT 

July 25 (Reuters) - Glaxosmithkline Plc :VIIV HEALTHCARE AND NEAT-ID ANNOUNCED RESULTS FROM NEAT 022 STUDY OF MORE THAN 400 PATIENTS WITH HIV AND HIGH CARDIOVASCULAR RISK.  Full Article

GSK says submits U.S. regulatory filing for asthma drug
Monday, 24 Jul 2017 08:20am EDT 

July 24 (Reuters) - Glaxosmithkline Plc ::GSK SUBMITS US REGULATORY FILING OF ARNUITY ELLIPTA IN CHILDREN WITH ASTHMA.FILING OF SNDA TO FDA FOR USE OF ARNUITY ELLIPTA AS MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN CHILDREN AGED 5-11 YRS.  Full Article

Photo

China biotech's 'coming out party' masks long road ahead

LONDON/SHANGHAI Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West.